Tong Ren Tang Technologies Co Ltd Class H (HK:1666)
:1666
Want to see HK:1666 full AI Analyst Report?
1666 Stock Chart & Stats
HK$4.49
-HK$0.01(-0.20%)
At close: 4:00 PM EST
HK$4.49
-HK$0.01(-0.20%)
Day’s Range― - ―
52-Week RangeHK$3.82 - HK$5.52
Previous CloseN/A
Volume468.00K
Average Volume (3M)1.05M
Market Cap
HK$4.93B
Enterprise ValueHK$1.76B
Total Cash (Recent Filing)HK$4.84B
Total Debt (Recent Filing)HK$2.17B
Price to Earnings (P/E)13.1
Beta0.76
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.47%
Share Statistics
EPS (TTM)0.05
Shares Outstanding628,704,000
10 Day Avg. Volume1,287,300
30 Day Avg. Volume1,053,233
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)0.69
Price to Sales (P/S)0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$5.50Price Target Upside22.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.35
Revenue Forecast (FY)HK$7.00B
Bulls Say, Bears Say
Bulls Say
Strong TCM BrandTong Ren Tang's recognized TCM brand and heritage provide durable competitive advantage in trust-driven healthcare products. Brand equity supports premium positioning, channel access and repeat customer demand, underpinning sustainable revenue sources and resilience versus newer entrants.
Improving Balance SheetLeverage reduction and steady equity growth signal stronger financial flexibility and lower balance-sheet risk. A contained debt-to-equity (~0.30) supports investment, working-capital management and capacity to withstand shocks without resorting to dilutive financing.
2025 Cash-flow ReboundA strong operating cash-flow and positive free cash flow in 2025 materially improves the company's ability to self-fund capex, R&D and distributions. Robust FCF enhances strategic optionality and reduces near-term reliance on external funding for growth initiatives.
Bears Say
Revenue DeclineA meaningful revenue contraction (-9.1% in 2025) indicates weakening end-market demand or loss of momentum. Sustained top-line decline compresses operating leverage, limits reinvestment capacity and raises strategic urgency to restore growth over the medium term.
Margin CompressionSequential margin erosion at both gross and net levels points to cost or pricing pressure that erodes profitability. Even with positive EBIT/EBITDA margins, declining margins weaken return on capital and could force either cost restructuring or margin recovery initiatives.
Volatile Cash ConversionExtreme swings in cash conversion across years indicate working-capital sensitivity and unpredictable cash generation. Such volatility complicates forecasting, increases financing risk during downturns and undermines confidence in sustaining investment or payout policies.
Tong Ren Tang Technologies Co News
1666 FAQ
What was Tong Ren Tang Technologies Co Ltd Class H’s price range in the past 12 months?
Tong Ren Tang Technologies Co Ltd Class H lowest stock price was HK$3.82 and its highest was HK$5.52 in the past 12 months.
What is Tong Ren Tang Technologies Co Ltd Class H’s market cap?
Tong Ren Tang Technologies Co Ltd Class H’s market cap is HK$4.93B.
When is Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date?
Tong Ren Tang Technologies Co Ltd Class H’s upcoming earnings report date is Aug 28, 2026 which is in 120 days.
How were Tong Ren Tang Technologies Co Ltd Class H’s earnings last quarter?
Tong Ren Tang Technologies Co Ltd Class H released its earnings results on Mar 27, 2026. The company reported HK$0.049 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.049.
Is Tong Ren Tang Technologies Co Ltd Class H overvalued?
According to Wall Street analysts Tong Ren Tang Technologies Co Ltd Class H’s price is currently Undervalued.
Does Tong Ren Tang Technologies Co Ltd Class H pay dividends?
Tong Ren Tang Technologies Co Ltd Class H pays a Annually dividend of HK$0.197 which represents an annual dividend yield of 4.47%. See more information on Tong Ren Tang Technologies Co Ltd Class H dividends here
What is Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate?
Tong Ren Tang Technologies Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tong Ren Tang Technologies Co Ltd Class H have?
Tong Ren Tang Technologies Co Ltd Class H has 628,704,000 shares outstanding.
What happened to Tong Ren Tang Technologies Co Ltd Class H’s price movement after its last earnings report?
Tong Ren Tang Technologies Co Ltd Class H reported an EPS of HK$0.049 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.752%.
Which hedge fund is a major shareholder of Tong Ren Tang Technologies Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:1666
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tong Ren Tang Technologies Co Ltd Class H
Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China and Hong Kong. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and foot care products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services. In addition, it is involved in the technological development and sale of biological products, Chinese and Western medicines, cosmetics, and healthcare products; wholesale and retail sale of Chinese medicines and healthcare products; and internal and external surgery, medical examination, and hospital management activities. Further, it produces and processes biochemical products; extracts and processes plants; and produces food and daily chemical products, and medical services. The company was founded in 1669 and is based in Beijing, the People's Republic of China.
1666 Stock 12 Month Forecast
Average Price Target
HK$5.50
▲(22.49% Upside)
Technical Analysis
Beijing Tong Ren Tang Chinese Medicine Co
―
China Traditional Chinese Medicine Holdings Co
―
CSPC Pharmaceutical Group
―
Wai Yuen Tong Medicine Holdings Limited
―
Pak Fah Yeow International Limited
―
Options Prices
Currently, No data available
---